This Article Full Text Full Text (PDF) All Versions of this Article: 110/6/724    most recent 01.CIR.0000138934.28340.EDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masoudi, F. A. Articles by Krumholz, H. M. Search for Related Content PubMed PubMed Citation Articles by Masoudi, F. A. Articles by Krumholz, H. M. Related Collections Health policy and outcome research Congestive Other Treatment

(Circulation. 2004;110:724-731.)
© 2004 American Heart Association, Inc.

Original Articles

National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction

Frederick A. Masoudi, MD, MSPH; Saif S. Rathore, MPH; Yongfei Wang, MS; Edward P. Havranek, MD; Jeptha P. Curtis, MD; JoAnne Micale Foody, MD; Harlan M. Krumholz, MD

From the Department of Medicine, Denver Health Medical Center (F.A.M., E.P.H.) and the Department of Medicine, University of Colorado Health Sciences Center (F.A.M., E.P.H.), Denver, Colo; Colorado Foundation for Medical Care (F.A.M., E.P.H., H.M.K.), Aurora, Colo; the Department of Internal Medicine (S.S.R., Y.W., J.P.C., J.M.F., H.M.K.) and the Department of Epidemiology and Public Health (H.M.K.), Yale University School of Medicine, and the Center for Outcomes Research and Evaluation (H.M.K.), Yale-New Haven Hospital, New Haven, Conn.

Correspondence to Frederick A. Masoudi, MD, MSPH, Division of Cardiology, MC 0960, DHMC, 777 Bannock St, Denver, CO 80204. E-mail fred.masoudi{at}uchsc.edu

Received April 14, 2004; revision received June 7, 2004; accepted June 15, 2004.

Background— Although ACE inhibitors are underprescribed for heart failure, factors associated with their use are not well described. Furthermore, the effectiveness of ACE inhibitors has been questioned in some populations, potentially contributing to underuse. Our objectives were to assess the correlates of ACE inhibitor use and the relationship between ACE inhibitor prescription and mortality in older patients with heart failure.

Methods and Results— We studied a national sample aged 65 years who had survived hospitalization for heart failure between April 1998 and March 1999 or July 2000 and June 2001, restricting the analysis to patients with left ventricular systolic dysfunction and without a documented contraindication to use of ACE inhibitors (n=17 456). Factors associated with ACE inhibitor prescription at discharge and the relationship between ACE inhibitor prescription and death within 1 year were assessed with hierarchical logistic models. Secondary analyses assessed therapeutic substitution with angiotensin receptor blockers (ARBs). ACE inhibitors were prescribed to only 68% of this ideal cohort, and 76% received either an ACE inhibitor or an ARB. Patient, physician, and hospital factors were weak predictors of prescription, except for serum creatinine (RR for 133 to 221 µmol/L=0.87, 95% CI 0.85 to 0.89; RR for 222 µmol/L=0.53, 95% CI 0.49 to 0.57 compared with 132 µmol/L). ACE inhibitor prescription was associated with lower crude 1-year mortality (33.0% versus 42.1%, P<0.001), lower risk of death after adjustment (RR 0.86, 95% CI 0.82 to 0.90), and lower mortality regardless of patient gender, age, race, or serum creatinine level.

Conclusions— ACE inhibitors were widely underprescribed despite evidence of a favorable impact on survival in a broad range of patients with heart failure. These results emphasize the importance of ongoing efforts to translate clinical trial results into practice.

Key Words: heart failure • aging • risk factors • follow-up studies • mortality

This article has been cited by other articles:

				V. Baliga and R. Sapsford Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 164 - 171. [Abstract] [PDF]

				A. F. Hernandez and G. C. Fonarow BNP-Guided Heart Failure Therapy in Older Patients JAMA, May 27, 2009; 301(20): 2091 - 2092. [Full Text] [PDF]

				P. S. Jhund, K. MacIntyre, C. R. Simpson, J. D. Lewsey, S. Stewart, A. Redpath, J. W.T. Chalmers, S. Capewell, and J. J.V. McMurray Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People Circulation, February 3, 2009; 119(4): 515 - 523. [Abstract] [Full Text] [PDF]

				M. Komajda, O. Hanon, M. Hochadel, J. L. Lopez-Sendon, F. Follath, P. Ponikowski, V.-P. Harjola, H. Drexler, K. Dickstein, L. Tavazzi, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II Eur. Heart J., February 2, 2009; 30(4): 478 - 486. [Abstract] [Full Text] [PDF]

				P. de Groote, R. Isnard, P. Clerson, G. Jondeau, M. Galinier, P. Assyag, N. Demil, A. Ducardonnet, J.-F. Thebaut, and M. Komajda Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology: The Impact-Reco Programme Eur J Heart Fail, January 1, 2009; 11(1): 85 - 91. [Abstract] [Full Text] [PDF]

				P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF]

				H. M. Krumholz, E. H. Bradley, B. K. Nallamothu, H. H. Ting, W. B. Batchelor, E. Kline-Rogers, A. F. Stern, J. R. Byrd, and J. E. Brush Jr A campaign to improve the timeliness of primary percutaneous coronary intervention: Door-to-Balloon: An Alliance for Quality. J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 97 - 104. [Abstract] [Full Text] [PDF]

				P. de Groote, R. Isnard, P. Assyag, P. Clerson, A. Ducardonnet, M. Galinier, G. Jondeau, I. Leurs, J.-F. Thebaut, and M. Komajda Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey Eur J Heart Fail, December 1, 2007; 9(12): 1205 - 1211. [Abstract] [Full Text] [PDF]

				M. Gianni, J. Bosch, J. Pogue, J. Probstfield, G. Dagenais, S. Yusuf, and E. Lonn Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients Eur. Heart J., June 1, 2007; 28(11): 1382 - 1388. [Abstract] [Full Text] [PDF]

				P. N. Peterson and F. A. Masoudi Cardiovascular disease and the elderly: can the evidence base avoid irrelevance? Eur. Heart J., June 1, 2007; 28(11): 1277 - 1278. [Full Text] [PDF]

				G. C. Fonarow, W. T. Abraham, N. M. Albert, W. G. Stough, M. Gheorghiade, B. H. Greenberg, C. M. O'Connor, K. Pieper, J. L. Sun, C. Yancy, et al. Association Between Performance Measures and Clinical Outcomes for Patients Hospitalized With Heart Failure JAMA, January 3, 2007; 297(1): 61 - 70. [Abstract] [Full Text] [PDF]

				H. M. Krumholz, S.-L. T. Normand, J. A. Spertus, D. M. Shahian, and E. H. Bradley Measuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement Health Aff., January 1, 2007; 26(1): 75 - 85. [Abstract] [Full Text] [PDF]

				P. J. Hauptman, M. A. Schnitzler, J. Swindle, and T. E. Burroughs Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA, October 18, 2006; 296(15): 1877 - 1884. [Abstract] [Full Text] [PDF]

				R. H. Mehta, M. T. Roe, A. Y. Chen, B. L. Lytle, C. V. Pollack Jr, R. G. Brindis, S. C. Smith Jr, R. A. Harrington, D. Fintel, E. S. Fraulo, et al. Recent Trends in the Care of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE Initiative. Arch Intern Med, October 9, 2006; 166(18): 2027 - 2034. [Abstract] [Full Text] [PDF]

				B. K. Nallamothu, S. Payvar, Y. Wang, M. Kosiborod, F. A. Masoudi, E. P. Havranek, J. M. Foody, S. W. Casscells, and H. M. Krumholz Admission Body Temperature and Mortality in Elderly Patients Hospitalized for Heart Failure J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2563 - 2564. [Full Text] [PDF]

				G. L. Smith, J. H. Lichtman, M. B. Bracken, M. G. Shlipak, C. O. Phillips, P. DiCapua, and H. M. Krumholz Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1987 - 1996. [Abstract] [Full Text] [PDF]

				R. W. Schrier Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor? J. Am. Coll. Cardiol., January 3, 2006; 47(1): 1 - 8. [Abstract] [Full Text]

				P. Verdecchia, F. Angeli, R. Gattobigio, and G. P. Reboldi Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur. Heart J., November 2, 2005; 26(22): 2381 - 2386. [Abstract] [Full Text] [PDF]

				G. H Skrepnek, J. Abarca, D. C Malone, E. P Armstrong, F. M Shirazi, and R. L Woosley Incremental Effects of Concurrent Pharmacotherapeutic Regimens for Heart Failure on Hospitalizations and Costs Ann. Pharmacother., November 1, 2005; 39(11): 1785 - 1791. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, C. A. Baillie, Y. Wang, W. D. Bradford, J. F. Steiner, E. P. Havranek, J. M. Foody, and H. M. Krumholz The Complexity and Cost of Drug Regimens of Older Patients Hospitalized With Heart Failure in the United States, 1998-2001 Arch Intern Med, October 10, 2005; 165(18): 2069 - 2076. [Abstract] [Full Text] [PDF]

				H. M. Krumholz The Year in Epidemiology, Health Services, and Outcomes Research J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1362 - 1370. [Full Text] [PDF]

				D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF]

				J. McMurray, A. Cohen-Solal, R. Dietz, E. Eichhorn, L. Erhardt, F.D. R. Hobbs, H. Krum, A. Maggioni, R. S. McKelvie, I. L. Pina, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice Eur J Heart Fail, August 1, 2005; 7(5): 710 - 721. [Abstract] [Full Text] [PDF]

				T. Sabatini, R. Rozzini, M. Trabucchi, F. A. Masoudi, E. P. Havranek, S. S. Rathore, Y. Wang, J. P. Curtis, J. M. Foody, and H. M. Krumholz Letter Regarding Article by Masoudi et al, "National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction" * Response Circulation, May 3, 2005; 111(17): e276 - e277. [Full Text] [PDF]

				B. J Epstein and J. G Gums Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations Ann. Pharmacother., March 1, 2005; 39(3): 470 - 480. [Abstract] [Full Text] [PDF]

				J. S. Rumsfeld and F. A. Masoudi Heart failure disease management works, but will it succeed? Eur. Heart J., September 2, 2004; 25(18): 1565 - 1567. [Full Text] [PDF]

				M. A. Hlatky Underuse of Evidence-Based Therapies Circulation, August 10, 2004; 110(6): 644 - 645. [Full Text] [PDF]